The study was conducted in 41 centers in China and enrolled 102 patients, including 41 (40.2%) with PTCL-NOS, 23 (22.5%) with ENKTL, 12 (11.8%) with ALK− ALCL, 7 (6.9%) with ALK+ ALCL, and 19 (18.6%) with other PTCL subtypes. Here, ALK is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.